Birdwatch Note
2024-02-18 05:10:55 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
彼らがターボ癌と呼ぶ疾病は現実には存在が確認されていません。 日本の場合、全がん種でも個別がん種でも新型コロナワクチン接種開始前後で死亡数の傾向変化は見られません。 https://www.mhlw.go.jp/toukei/list/81-1a.html 米国CDCのデータでもがん死亡の傾向の変化は見られません。 https://data.cdc.gov/NCHS/Weekly-Counts-of-Deaths-by-State-and-Select-Causes/3yf8-kanr https://data.cdc.gov/NCHS/Weekly-Provisional-Counts-of-Deaths-by-State-and-S/muzy-jte6/data 厚労省は新型コロナワクチンの有効性や安全性を科学的かつ徹底的に検証しています。 https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html 世界中の継続した検証でも接種後の危険性を裏付ける科学的根拠はありません。 https://www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.cov19-vaccine.mhlw.go.jp/qa/0170.html https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html 信頼できる情報源からの情報収集に努めましょう。 https://www.cov19-vaccine.mhlw.go.jp/qa/0075.html https://togetter.com/li/2195650 https://togetter.com/li/2176345 https://togetter.com/li/2174198 代替医療にがんの治療効果がないことは既に明らかになっています。 https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1758983514748498265
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1759083047184638129
- noteId - 1759083047184638129
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1708233055291
- tweetId - 1758983514748498265
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 彼らがターボ癌と呼ぶ疾病は現実には存在が確認されていません。 日本の場合、全がん種でも個別がん種でも新型コロナワクチン接種開始前後で死亡数の傾向変化は見られません。 https://www.mhlw.go.jp/toukei/list/81-1a.html 米国CDCのデータでもがん死亡の傾向の変化は見られません。 https://data.cdc.gov/NCHS/Weekly-Counts-of-Deaths-by-State-and-Select-Causes/3yf8-kanr https://data.cdc.gov/NCHS/Weekly-Provisional-Counts-of-Deaths-by-State-and-S/muzy-jte6/data 厚労省は新型コロナワクチンの有効性や安全性を科学的かつ徹底的に検証しています。 https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html 世界中の継続した検証でも接種後の危険性を裏付ける科学的根拠はありません。 https://www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.cov19-vaccine.mhlw.go.jp/qa/0170.html https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html 信頼できる情報源からの情報収集に努めましょう。 https://www.cov19-vaccine.mhlw.go.jp/qa/0075.html https://togetter.com/li/2195650 https://togetter.com/li/2176345 https://togetter.com/li/2174198 代替医療にがんの治療効果がないことは既に明らかになっています。 https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-02-18 05:10:55 UTC (1708233055291) |
2024-02-19 07:16:15 UTC (1708326975422) |
CURRENTLY_RATED_HELPFUL | 2024-02-19 09:04:13 UTC (1708333453151) |
CURRENTLY_RATED_HELPFUL | 2024-02-19 07:16:15 UTC (1708326975422) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-02-18 22:01:13 -0600 | Rating Details | |
| 2024-02-18 19:02:42 -0600 | Rating Details | |
| 2024-02-18 12:33:00 -0600 | Rating Details | |
| 2024-02-18 11:16:39 -0600 | Rating Details | |
| 2024-02-18 07:08:06 -0600 | Rating Details | |
| 2024-02-18 06:01:51 -0600 | Rating Details | |
| 2024-02-18 04:03:54 -0600 | Rating Details | |
| 2024-02-18 03:50:51 -0600 | Rating Details | |
| 2024-02-18 03:42:59 -0600 | Rating Details | |
| 2024-02-18 03:35:32 -0600 | Rating Details | |
| 2024-02-18 03:29:21 -0600 | Rating Details | |
| 2024-02-18 03:03:15 -0600 | Rating Details | |
| 2024-02-18 02:58:09 -0600 | Rating Details | |
| 2024-02-18 01:42:01 -0600 | Rating Details | |
| 2024-02-18 01:22:52 -0600 | Rating Details | |
| 2024-02-18 01:07:59 -0600 | Rating Details | |
| 2024-02-18 01:00:48 -0600 | Rating Details | |
| 2024-02-18 00:36:06 -0600 | Rating Details | |
| 2024-02-18 00:34:22 -0600 | Rating Details | |
| 2024-02-18 00:28:05 -0600 | Rating Details | |
| 2024-02-18 00:14:55 -0600 | Rating Details | |
| 2024-02-18 00:11:27 -0600 | Rating Details | |
| 2024-02-18 00:09:34 -0600 | Rating Details | |
| 2024-02-18 00:06:47 -0600 | Rating Details | |
| 2024-02-17 23:54:27 -0600 | Rating Details | |
| 2024-02-17 23:53:27 -0600 | Rating Details | |
| 2024-02-17 23:52:04 -0600 | Rating Details | |
| 2024-02-17 23:43:18 -0600 | Rating Details | |
| 2024-02-17 23:42:32 -0600 | Rating Details | |
| 2024-02-17 23:42:22 -0600 | Rating Details | |
| 2024-02-17 23:41:35 -0600 | Rating Details | |
| 2024-02-17 23:37:07 -0600 | Rating Details | |
| 2024-02-17 23:36:47 -0600 | Rating Details | |
| 2024-02-17 23:35:48 -0600 | Rating Details | |
| 2024-02-17 23:33:51 -0600 | Rating Details | |
| 2024-02-17 23:30:58 -0600 | Rating Details | |
| 2024-02-17 23:23:53 -0600 | Rating Details | |
| 2024-02-17 23:22:23 -0600 | Rating Details | |
| 2024-02-17 23:17:23 -0600 | Rating Details | |
| 2024-02-17 23:12:43 -0600 | Rating Details | |
| 2024-02-19 09:31:46 -0600 | Rating Details | |
| 2024-02-19 01:44:26 -0600 | Rating Details | |
| 2024-02-23 21:10:39 -0600 | Rating Details | |
| 2024-02-23 19:32:50 -0600 | Rating Details | |
| 2024-02-25 01:56:29 -0600 | Rating Details | |
| 2024-02-24 03:24:46 -0600 | Rating Details | |
| 2024-02-23 07:30:24 -0600 | Rating Details | |
| 2024-02-18 23:57:05 -0600 | Rating Details | |
| 2024-02-18 23:39:58 -0600 | Rating Details | |
| 2024-02-18 20:10:17 -0600 | Rating Details | |
| 2024-02-18 03:29:14 -0600 | Rating Details | |
| 2024-02-18 03:10:11 -0600 | Rating Details | |
| 2024-02-18 02:49:53 -0600 | Rating Details | |
| 2024-02-18 02:48:17 -0600 | Rating Details | |
| 2024-02-18 02:39:05 -0600 | Rating Details | |
| 2024-02-18 02:32:16 -0600 | Rating Details | |
| 2024-02-18 02:02:36 -0600 | Rating Details | |
| 2024-02-18 01:39:27 -0600 | Rating Details | |
| 2024-02-18 01:13:56 -0600 | Rating Details | |
| 2024-02-18 00:58:05 -0600 | Rating Details | |
| 2024-02-18 00:30:18 -0600 | Rating Details | |
| 2024-02-18 00:27:46 -0600 | Rating Details | |
| 2024-02-18 00:22:46 -0600 | Rating Details | |
| 2024-02-18 00:06:22 -0600 | Rating Details | |
| 2024-02-18 00:03:19 -0600 | Rating Details | |
| 2024-02-17 23:54:24 -0600 | Rating Details | |
| 2024-02-17 23:53:54 -0600 | Rating Details | |
| 2024-02-17 23:47:24 -0600 | Rating Details | |
| 2024-02-17 23:47:08 -0600 | Rating Details | |
| 2024-02-17 23:45:48 -0600 | Rating Details | |
| 2024-02-17 23:42:33 -0600 | Rating Details | |
| 2024-02-17 23:40:55 -0600 | Rating Details | |
| 2024-02-17 23:37:01 -0600 | Rating Details | |
| 2024-02-17 23:31:41 -0600 | Rating Details | |
| 2024-02-17 23:27:29 -0600 | Rating Details | |
| 2024-02-17 23:25:44 -0600 | Rating Details | |
| 2024-02-17 23:25:15 -0600 | Rating Details | |
| 2024-02-17 23:24:23 -0600 | Rating Details | |
| 2024-02-23 22:47:15 -0600 | Rating Details | |
| 2024-02-23 22:29:06 -0600 | Rating Details | |
| 2024-02-23 20:01:06 -0600 | Rating Details | |
| 2024-02-20 08:44:24 -0600 | Rating Details | |
| 2024-02-19 21:22:24 -0600 | Rating Details | |
| 2024-03-31 00:54:13 -0500 | Rating Details | |
| 2024-08-09 05:10:37 -0500 | Rating Details |